

Aleksey Kurylev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8632193/publications.pdf>

Version: 2024-02-01

25
papers

46
citations

2258059

3
h-index

1872680

6
g-index

25
all docs

25
docs citations

25
times ranked

101
citing authors

#	ARTICLE	IF	CITATIONS
1	A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 148-156.	2.2	24
2	What should be considered if you decide to build your own mathematical model for predicting the development of bacterial resistance? Recommendations based on a systematic review of the literature. <i>Frontiers in Microbiology</i> , 2015, 6, 352.	3.5	8
3	Retrospective surveillance of antibiotic use in maternity wards and neonatal intensive care units in Saint Petersburg, Russia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1531-1537.	2.9	8
4	THE COMBINED EFFECT OF CYP2D6 AND DRD2 Taq1A POLYMORPHISMS ON THE ANTIPSYCHOTICS DAILY DOSES AND HOSPITAL STAY DURATION IN SCHIZOPHRENIA INPATIENTS (OBSERVATIONAL NATURALISTIC) Tj ETQq0.0 rgB8/Overlock	0.4	0
5	Pharmacoeconomic Analysis of the use of Everolimus Compared to Axitinib in Second Line Therapy of Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2015, 18, A442.	0.3	1
6	Development Of Predictive Models For The Analysis Of The List Of Vital Essential And Necessary Drugs Compilation. <i>Value in Health</i> , 2016, 19, A448.	0.3	1
7	Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy. <i>Problemy Endokrinologii</i> , 2017, 63, 307-319.	0.8	1
8	First Russian Type 2 Diabetes Mellitus Simulation Model with Discrete Events Modeling. Health-Economic Analysis. <i>Value in Health</i> , 2013, 16, A437-A438.	0.3	0
9	Cost-Effectiveness Analysis of Use of Dydrogesterone in Premenstrual Syndrome. <i>Value in Health</i> , 2014, 17, A508.	0.3	0
10	Budget Impact Analysis of the Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors â€“ Nilotinib in the First and Second Lines of Therapy. <i>Value in Health</i> , 2015, 18, A443.	0.3	0
11	Investigating Levels of Bacterial Resistance and Antibiotic Consumption in the St. Petersburg State Medical University. <i>Value in Health</i> , 2015, 18, A515-A516.	0.3	0
12	Low-Density Lipoprotein Cholesterol Lowering Efficacy of Evolocumab May Reduce Need for Apheresis in Heterozygous Familial Hypercholesterolaemia Patients According to Russian Guidelines. <i>Value in Health</i> , 2016, 19, A654.	0.3	0
13	Parametric and Non-Parametric Approaches for Predicting Bacterial Resistance. <i>Value in Health</i> , 2016, 19, A441-A442.	0.3	0
14	Pharmacoepidemiology of Antimicrobials in Pregnant Women And Women After Childbirth In Russia, Retrospective Analysis of Medical Records. <i>Clinical Therapeutics</i> , 2017, 39, e2.	2.5	0
15	The Analysis Of Final And Surrogate Effectiveness Criteria Used In Health Economic Studies Of Drugs Submitted Into The Reimbursement In Russia In 2016. <i>Value in Health</i> , 2017, 20, A678.	0.3	0
16	Pharmacoeconomic Analysis of Trastuzumab Emtanzine in Patients with Metastatic Breast Cancer and Central Nervous System Metastases. <i>Value in Health</i> , 2017, 20, A438.	0.3	0
17	Pharmacoeconomic Analysis of Ixabepilone Monotherapy in Patients with Advanced or Metastatic Breast Cancer Resistant To Anthracyclines, Taxanes and Capecitabine. <i>Value in Health</i> , 2017, 20, A440.	0.3	0
18	PHP107 - THE STRUCTURE OF CONSUMPTION OF ANTIMICROBIAL DRUG FOR SYSTEMIC USE IN MULTIDISCIPLINARY HOSPITALS IN ST.PETERSBURG IN 2014-2015. <i>Value in Health</i> , 2018, 21, S168.	0.3	0

#	ARTICLE	IF	CITATIONS
19	PMH39 - HEALTH-ECONOMIC EVALUATION OF PHARMACOGENETIC TESTS IN PSYCHIATRIC IN-PATIENT CARE. Value in Health, 2018, 21, S281.	0.3	0
20	PRS47 - PHARMACOECONOMIC ANALISYS OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. Value in Health, 2018, 21, S412.	0.3	0
21	PDG1 RECOMBINANT HUMAN ERYTHROPOIETIN VERSUS PLACEBO OR NO TREATMENT IN PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Value in Health, 2019, 22, S597.	0.3	0
22	PDB67 MAIN PREDICTORS OF DIABETES MELLITUS TYPE 2 (DM2T) IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S585.	0.3	0
23	PCN260 REVIEW OF BREAST CANCER MATHEMATIC AND EPIDEMIOLOGY MODELS. Value in Health, 2019, 22, S486.	0.3	0
24	PND52 The Burden of Spinal Muscular Atrophy in Russia. Value in Health, 2020, 23, S632.	0.3	0
25	POSB42 The Health-Economic Evaluation of Risdiplam in Patients with Spinal Muscular Atrophy. Value in Health, 2022, 25, S68.	0.3	0